These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1855348)

  • 1. No causal relationship between transdermal scopolamine and seizures: methodologic lessons for pharmacoepidemiology.
    Strom BL; Carson JL; Schinnar R; Snyder ES; Shaw M; Waiter SL
    Clin Pharmacol Ther; 1991 Jul; 50(1):107-13. PubMed ID: 1855348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
    Patel PN; Ezzo DC
    Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side effects of transdermal scopolamine.
    Wilkinson JA
    J Emerg Med; 1987; 5(5):389-92. PubMed ID: 3668203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alleviation of induced vertigo. Therapy with transdermal scopolamine and oral meclizine.
    Schmitt LG; Shaw JE
    Arch Otolaryngol Head Neck Surg; 1986 Jan; 112(1):88-91. PubMed ID: 3940518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual side-effects from transdermal scopolamine (hyoscine).
    Firth AY; Walker K
    Dev Med Child Neurol; 2006 Feb; 48(2):137-8. PubMed ID: 16417670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of double-dose transdermal scopolamine.
    Bar R; Gil A; Tal D
    Pharmacotherapy; 2009 Sep; 29(9):1082-8. PubMed ID: 19698013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal scopolamine as a cause of transient psychosis in two elderly patients.
    Mego DM; Omori JM; Hanley JF
    South Med J; 1988 Mar; 81(3):394-5. PubMed ID: 3347867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxic psychosis from transdermal scopolamine in a child.
    Sennhauser FH; Schwarz HP
    Lancet; 1986 Nov; 2(8514):1033. PubMed ID: 2877187
    [No Abstract]   [Full Text] [Related]  

  • 10. Transdermal scopolamine in drooling.
    Brodtkorb E; Wyzocka-Bakowska MM; Lillevold PE; Sandvik L; Saunte C; Hestnes A
    J Ment Defic Res; 1988 Jun; 32 ( Pt 3)():233-7. PubMed ID: 3047394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal scopolamine intoxication in a child.
    Klein BL; Ashenburg CA; Reed MD
    Pediatr Emerg Care; 1985 Dec; 1(4):208-9. PubMed ID: 3842169
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J; Gordon C; Ribak J; Binah O; Rolnick A
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quality of Medicaid and Medicare data obtained from CMS and its contractors: implications for pharmacoepidemiology.
    Leonard CE; Brensinger CM; Nam YH; Bilker WB; Barosso GM; Mangaali MJ; Hennessy S
    BMC Health Serv Res; 2017 Apr; 17(1):304. PubMed ID: 28446159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prochlorperazine and transdermal scopolamine added to a metoclopramide antiemetic regimen. A controlled comparison.
    Malone JM; Christensen CW; Yashinsky D; Malviya VK; Deppe G
    J Reprod Med; 1990 Oct; 35(10):932-4. PubMed ID: 2246759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed hypersensitivity to scopolamine in transdermal therapeutic systems.
    van der Willigen AH; Oranje AP; Stolz E; van Joost T
    J Am Acad Dermatol; 1988 Jan; 18(1 Pt 1):146-7. PubMed ID: 3346401
    [No Abstract]   [Full Text] [Related]  

  • 16. Central anticholinergic syndrome in a pediatric patient following transdermal scopolamine patch placement.
    Holland MS
    Nurse Anesth; 1992 Sep; 3(3):121-4. PubMed ID: 1445954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal scopolamine-induced neurologic deficits in patients with cancer.
    Friedberg MH; Glantz MJ
    R I Med; 1994 May; 77(5):141-2. PubMed ID: 8019013
    [No Abstract]   [Full Text] [Related]  

  • 18. Transdermal scopolamine use in the control of narcotic-induced nausea.
    Ferris FD; Kerr IG; Sone M; Marcuzzi M
    J Pain Symptom Manage; 1991 Aug; 6(6):389-93. PubMed ID: 1880439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nausea prophylaxis using transdermal scopolamine in the setting of patient-controlled analgesia.
    Harris SN; Sevarino FB; Sinatra RS; Preble L; O'Connor TZ; Silverman DG
    Obstet Gynecol; 1991 Oct; 78(4):673-7. PubMed ID: 1923171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal scopolamine as treatment of bradyarrhythmias.
    Salas Nieto J; Ruiperez Abizanda JA; Pico Aracil F; de la Morena Valenzuela G; Ruiz Ros JA
    Chest; 1992 Jun; 101(6):1588-90. PubMed ID: 1600776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.